Cargando…

Therapeutic potential of PIMSR, a novel CB1 receptor neutral antagonist, for cocaine use disorder: evidence from preclinical research

Cannabinoid CB1 receptors (CB1Rs) have been major targets in medication development for the treatment of substance use disorders. However, clinical trials with rimonabant, a CB1R antagonist/inverse agonist, failed due to severe side effects. Here, we evaluated the therapeutic potential of PIMSR, a n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galaj, Ewa, Hempel, Briana, Moore, Allamar, Klein, Benjamin, Bi, Guo-Hua, Gardner, Eliot L., Seltzman, Herbert H., Xi, Zheng-Xiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293959/ https://www.ncbi.nlm.nih.gov/pubmed/35851573 http://dx.doi.org/10.1038/s41398-022-02059-w

Ejemplares similares

PM288. Preclinical Evaluation of Neutral Cannabinoid CB1 Receptor Antagonists and Cannabinoid CB1 Receptor Negative Allosteric Modulators for Treating Drug Addiction
por: Gardner, Eliot L., et al.
Publicado: (2016)

β-caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms
por: He, Xiang-Hu, et al.
Publicado: (2021)

Involvement of the ghrelin system in the maintenance and reinstatement of cocaine-motivated behaviors: a role of adrenergic action at peripheral β1 receptors
por: You, Zhi-Bing, et al.
Publicado: (2021)

Brain Cannabinoid CB(2) Receptors Modulate Cocaine’s Actions in Mice
por: Xi, Zheng-Xiong, et al.
Publicado: (2011)

Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge
por: Soler-Cedeno, Omar, et al.
Publicado: (2022)

mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism
por: Li, Xia, et al.
Publicado: (2018)

Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers
por: Tudge, Luke, et al.
Publicado: (2015)

Effects of Cocaine Self-Administration and Its Extinction on the Rat Brain Cannabinoid CB1 and CB2 Receptors
por: Bystrowska, Beata, et al.
Publicado: (2018)

A highly D(3)R-selective and efficacious partial agonist (S)-ABS01-113 compared to its D(3)R-selective antagonist enantiomer (R)-ABS01-113 as potential treatments for opioid use disorder
por: Galaj, Ewa, et al.
Publicado: (2022)

Pharmacological blockade of either cannabinoid CB(1) or CB(2) receptors prevents both cocaine-induced conditioned locomotion and cocaine-induced reduction of cell proliferation in the hippocampus of adult male rat
por: Blanco-Calvo, Eduardo, et al.
Publicado: (2014)

Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals
por: Galaj, Ewa, et al.
Publicado: (2020)

Attenuation of Cocaine-Induced Conditioned Place Preference and Motor Activity via Cannabinoid CB2 Receptor Agonism and CB1 Receptor Antagonism in Rats
por: Delis, Foteini, et al.
Publicado: (2016)

The impact of social variables in preclinical models of cocaine abuse
por: Nader, Michael A
Publicado: (2021)

Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia
por: Pan, Changyu, et al.
Publicado: (2011)

The rise and fall of CB(1) receptor antagonists: possible future perspectives
por: Bagdy, György
Publicado: (2011)

Endocannabinoids regulate cocaine-associated memory through brain AEA–CB1R signalling activation
por: Li, Hongchun, et al.
Publicado: (2022)

CB1 Receptor Activation on VgluT2-Expressing Glutamatergic Neurons Underlies Δ(9)-Tetrahydrocannabinol (Δ(9)-THC)-Induced Aversive Effects in Mice
por: Han, Xiao, et al.
Publicado: (2017)

The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers
por: Rzepa, Ewelina, et al.
Publicado: (2015)

The CB(1) Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability
por: Gueye, Aliou B., et al.
Publicado: (2016)

Peripheral CB1 Receptor Neutral Antagonist, AM6545, Ameliorates Hypometabolic Obesity and Improves Adipokine Secretion in Monosodium Glutamate Induced Obese Mice
por: Ma, Haiming, et al.
Publicado: (2018)

Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.
por: Foster, B. J., et al.
Publicado: (1993)

Repurposing antimalarial artesunate for the prophylactic treatment of depression: Evidence from preclinical research
por: Huang, Shihao, et al.
Publicado: (2022)

Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges
por: Galaj, Ewa, et al.
Publicado: (2020)

Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure
por: Banks, Matthew L., et al.
Publicado: (2015)

Regulation of glutamate homeostasis in the nucleus accumbens by astrocytic CB1 receptors and its role in cocaine-motivated behaviors
por: Zhang, Lan-Yuan, et al.
Publicado: (2022)

Differential effects of acute and chronic antagonist and an irreversible antagonist treatment on cocaine self-administration behavior in rats
por: Wetzel, Hanna N., et al.
Publicado: (2022)

Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB(1)R) Antagonist
por: Liu, Ziyi, et al.
Publicado: (2021)

Protocol for crystal structure determination of the antagonist-bound human cannabinoid receptor CB2
por: Shen, Ling, et al.
Publicado: (2021)

The α1 Antagonist Doxazosin Alters the Behavioral Effects of Cocaine in Rats
por: Haile, Colin N., et al.
Publicado: (2012)

Coupling of CB-2 and CB-1
por: Ansaldo
Publicado: (2003)

Cannabigerol Action at Cannabinoid CB(1) and CB(2) Receptors and at CB(1)–CB(2) Heteroreceptor Complexes
por: Navarro, Gemma, et al.
Publicado: (2018)

Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs
por: Murphy, Thomas, et al.
Publicado: (2020)

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
por: Timofeeva, Natalia, et al.
Publicado: (2023)

Effects of the cannabinoid CB(1) receptor antagonist rimonabant on distinct measures of impulsive behavior in rats
por: Pattij, Tommy, et al.
Publicado: (2007)

Preclinical support for the therapeutic potential of zolmitriptan as a treatment for cocaine use disorders
por: Garcia, Raul, et al.
Publicado: (2020)

Action of the Calcium Antagonists Cocaine and Ethanol on Contraction and Potassium Efflux of Smooth Muscle
por: Hurwitz, Leon, et al.
Publicado: (1962)

Mandatory minimum sentencing policies and cocaine use in the U.S., 1985–2013
por: Walker, Lauryn Saxe, et al.
Publicado: (2018)

PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice
por: Xi, Zheng-Xiong, et al.
Publicado: (2023)

Preclinical Evaluation of a Novel (99m)Tc-Labeled CB86 for Rheumatoid Arthritis Imaging
por: Liu, Peng, et al.
Publicado: (2020)

The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer
por: Vigolo, Michele, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p4bciubnf3av559ncgdgs4iuba